Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA Breast Cancer): an open-label, randomised, controlled, phase 2 study

Colaboración

Año: 2023

Hurvitz, SA; Bardia, A; Quiroga, V; Park, YH; Blancas, I; Alonso-Romero, JL; Vasiliev, A; Adamchuk, H; Salgado, M; Yardley, DA; Berzoy, O; Zamora-Auñón, P; Chan, DV; Spera, G; Xue, CR; Ferreira, E; Crnjevic, TB; Pérez-Moreno, PD; López-Valverde, V; Steins

Título: LANCET ONCOLOGY

• D1